Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Shredded cheese sold in dozens of states recalled due to potential for metal fragment contamination - 2Figure out How to Augment the Advantages of a Web-based Degree
- 3German finance minister seeks better market access in China talks
- 4More loons are filling Maine's lakes with their ghostlike calls
- 5Louisiana seeks California doctor’s extradition, testing the limits of shield laws
- Some gifted dogs can learn new toy names by eavesdropping on owners
- 2024's Savvy Home Gadgets for an Associated Way of life
- ‘Democratizing space’ is more than just adding new players – it comes with questions around sustainability and sovereignty
- My daughter is in the #1 movie in the country. She still has to finish her math homework.
- The most effective method to Augment Benefits in Gold Speculation: Systems and Tips
- How Seniors Can Use Refunds and Motivators to Purchase a Hyundai Ioniq EV
- Ukraine's naval drones are gunning for Russia's 'shadow fleet.' A security source says a tanker just suffered a critical hit.
- Interstellar comet 3I/ATLAS to pass closest to Earth on Friday
- Who plays Moana in the live-action remake? What to know about Catherine Lagaʻaia.
